{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.1","value":"6954.3"},{"groupId":"OG001","spread":"44.7","value":"7377.9"},{"groupId":"OG002","spread":"42.8","value":"2977.3"},{"groupId":"OG003","spread":"45.2","value":"9123.8"}]}],"title":"AUC(0 to 24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"62.1","value":"7292.0"},{"groupId":"OG001","spread":"49.9","value":"7703.4"},{"groupId":"OG002","spread":"45.0","value":"3096.9"},{"groupId":"OG003","spread":"48.5","value":"9727.7"}]}],"title":"AUC(0 to inf)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"61.6","value":"7227.1"},{"groupId":"OG001","spread":"49.9","value":"7657.6"},{"groupId":"OG002","spread":"44.4","value":"3053.9"},{"groupId":"OG003","spread":"48.9","value":"9597.1"}]}],"title":"AUC(0 to t)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"description":"Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. Besylate sub-study pharmacokinetic (PK) Parameter Population consisted of all participants in the PK Parameter Population who participated in the besylate substudy.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered GSK525762 80 mg amorphous free-base tablet along with 6 mg stable isotope in the fasted state.","id":"OG000","title":"GSK525762 80 mg Amorphous+6 mg Stable Isotope"},{"description":"Participants were administered GSK525762 80 mg besylate tablet along with 6 mg stable isotope in solution in fasted state.","id":"OG001","title":"GSK525762 80 mg Besylate+6 mg Stable Isotope"},{"description":"Participants were administered GSK525762 30 mg besylate tablet along with 6 mg stable isotope in solution in fasted state.","id":"OG002","title":"GSK525762 30 mg Besylate+6 mg Stable Isotope"},{"description":"Participants were administered GSK525762 80 mg besylate tablet along with Food and Drug Administration (FDA) recommended high fat breakfast.","id":"OG003","title":"GSK525762 80 mg Besylate Fed"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Besylate Sub-Study PK Parameter Population. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)","title":"Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study","type":"PRIMARY","unitOfMeasure":"Hours*nanograms per milliliter"}